Trial Profile
A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary)
- Indications CNS cancer; Diffuse intrinsic pontine glioma; Glioma; Medulloblastoma
- Focus Adverse reactions
- 13 Jan 2023 Planned End Date changed from 31 Dec 2023 to 31 Jan 2025.
- 13 Jan 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Jan 2025.
- 03 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.